Drug Trial Radar · NCT07413952
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge. Although EGFR-TKIs have demonstrated intracranial activity, disease control is still suboptimal in some patients. Limertinib (ASK120067) is a novel third-generation EGFR tyrosine kinase inhibitor with favorable central nervous system penetration and encouraging intracranial antitumor activity. The potential synergistic effect of limertinib combined with radiotherapy warrants further investigation. This prospective, multicenter, single-arm phase II study aims to evaluate the efficacy and safety of first-line limertinib combined with radiotherapy in this patient population.
Conditions
- NSCLC
Interventions
Limertinib Plus RadiotherapyDrug
Limertinib Plus Radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intracranial progression-free survival (iPFS)Time frame: Up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.